CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
April 23rd 2024
Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.
Offering Hope in the Lung Cancer Community
April 24th 2021In partnership with CURE®, Bonnie J. Addario and the GO2 Foundation for Lung Cancer will release “The Living Room: A Lung Cancer Community of Courage,” a collection of stories from patients, caregivers and survivors taking a personal approach to cancer care.
Cell-Based Therapies May ‘Level the Playing Field’ in Non-Small Cell Lung Cancer
April 20th 2021Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.
Obesity May Be Associated with Increased Cancer Mortality in Most Cancers; Lower in Others
April 14th 2021Recent study results demonstrated an possible association between a high BMI and risk of cancer and overall mortality, though patients with obesity and lung cancer, renal cell carcinoma and melanoma were found to have a lower risk of death than patients with the same cancers without obesity.
Newly-Approved Lorbrena Shows Better Responses in Patients With Brain Metastases
March 31st 2021The FDA recently approved an expanded indication for Lorbrena as a first-line treatment option for a subset of lung cancer that has spread to the brain. Compared to previously-approved options, experts say Lorbrena is more effective.
Opdivo With or Without Yervoy Did Not Prolong Survival in Small Cell Lung Cancer
March 29th 2021Previously, treatments for patients with extensive-disease small cell lung cancer were limited with a poor prognosis. Researchers sought to investigate if Opdivo plus Yervoy or Opdivo alone would improve survival.
FDA Fast Track of Novel Drug May Open Doors for Certain Patients with Non-Small Cell Lung Cancer
March 15th 2021The FDA’s fast track designation to poziotinib for use in previously treated patients with non-small cell lung cancer whose disease harbors a certain genetic mutation, may open the doors to an accelerated approval.
The Future of Adoptive Cellular Therapy in Lung Cancer
March 15th 2021In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.